Synthetic Nanovaccines for Immunotherapy

Overview

Journal J Control Release

Specialty Pharmacology

Date 2017 Mar 25

PMID 28336379

Citations 35

Authors

Min Luo

Layla Z Samandi

Zhaohui Wang

Zhijian J Chen

Jinming Gao

Affiliations

Soon will be listed here.

Abstract

Although vaccination is historically one of the most successful strategies for the prevention of infectious diseases, development of vaccines for cancer and many chronic infections, such as HIV, malaria, and tuberculosis, has remained a challenge. Strong and long-lasting antigen-specific T cell responses are critical for therapy of these diseases. A major challenge in achieving a robust CD8+ T cell response is the requirement of spatio-temporal orchestration of antigen cross-presentation in antigen-presenting cells with innate stimulation. Here, we discuss the development of nanoparticle vaccine (nanovaccine) that modulates the innate immune system and enhances adaptive immunity with reduced toxicity. We address how nanovaccines can integrate multiple functions, such as lymph node targeting, antigen presentation, and stimulation of innate immunity, to achieve a robust T cell response for immunotherapy.

Citing Articles

Adjuvant-free, self-assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses.

Zhao Y, Guo S, Liu J, Wang Y, Wang B, Peng C Front Immunol. 2025; 16:1519866.

PMID: 39958330 PMC: 11827429. DOI: 10.3389/fimmu.2025.1519866.

Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine.

Zhao Y, Liu J, Peng C, Guo S, Wang B, Chen L J Nanobiotechnology. 2025; 23(1):77.

PMID: 39905416 PMC: 11792681. DOI: 10.1186/s12951-025-03122-6.

Tracing Sentinel Lymph Nodes and Inhibiting Lymphatic Metastasis with TiN Nanobipyramids Through Photothermal Therapy.

Xu Y, Bai X, Chen J, Wu X, Yin D, Yuan G Int J Nanomedicine. 2024; 19:13579-13592.

PMID: 39720216 PMC: 11668323. DOI: 10.2147/IJN.S488480.

Precision Nanovaccines for Potent Vaccination.

Liu H, Chen H, Yang Z, Wen Z, Gao Z, Liu Z JACS Au. 2024; 4(8):2792-2810.

PMID: 39211600 PMC: 11350730. DOI: 10.1021/jacsau.4c00568.

Revolutionizing lymph node metastasis imaging: the role of drug delivery systems and future perspectives.

Cai Z, Li Z, Zhong N, Cao L, Xiao Y, Li J J Nanobiotechnology. 2024; 22(1):135.

PMID: 38553735 PMC: 10979629. DOI: 10.1186/s12951-024-02408-5.

References

Ballester M, Nembrini C, Dhar N, de Titta A, De Piano C, Pasquier M . Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine. 2011; 29(40):6959-66. DOI: 10.1016/j.vaccine.2011.07.039. View

Fidler I, Raz A, Fogler W, Kirsh R, Bugelski P, Poste G . Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res. 1980; 40(12):4460-6. View

Seong S, Matzinger P . Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004; 4(6):469-78. DOI: 10.1038/nri1372. View

Le D, Wang-Gillam A, Picozzi V, Greten T, Crocenzi T, Springett G . Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015; 33(12):1325-33. PMC: 4397277. DOI: 10.1200/JCO.2014.57.4244. View

Ahsan F, Rivas I, Khan M, Torres Suarez A . Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages. J Control Release. 2002; 79(1-3):29-40. DOI: 10.1016/s0168-3659(01)00549-1. View

Demento S, Bonafe N, Cui W, Kaech S, Caplan M, Fikrig E . TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J Immunol. 2010; 185(5):2989-97. PMC: 3753007. DOI: 10.4049/jimmunol.1000768. View

Poltorak A, He X, Smirnova I, Liu M, Van Huffel C, Du X . Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998; 282(5396):2085-8. DOI: 10.1126/science.282.5396.2085. View

Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J . Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015; 520(7549):692-6. PMC: 4838069. DOI: 10.1038/nature14426. View

Leonard J, Sherman M, Fisher G, Buchanan L, Larsen G, Atkins M . Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997; 90(7):2541-8. View

10.

van der Burg S, Arens R, Ossendorp F, van Hall T, Melief C . Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016; 16(4):219-33. DOI: 10.1038/nrc.2016.16. View

11.

Medzhitov R . Approaching the asymptote: 20 years later. Immunity. 2009; 30(6):766-75. DOI: 10.1016/j.immuni.2009.06.004. View

12.

Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H . A Toll-like receptor recognizes bacterial DNA. Nature. 2000; 408(6813):740-5. DOI: 10.1038/35047123. View

13.

Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A . Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016; 11(11):986-994. PMC: 5198777. DOI: 10.1038/nnano.2016.168. View

14.

Pulendran B, Ahmed R . Immunological mechanisms of vaccination. Nat Immunol. 2011; 12(6):509-17. PMC: 3253344. DOI: 10.1038/ni.2039. View

15.

Sahdev P, Ochyl L, Moon J . Biomaterials for nanoparticle vaccine delivery systems. Pharm Res. 2014; 31(10):2563-82. PMC: 4198431. DOI: 10.1007/s11095-014-1419-y. View

16.

Rappuoli R, Aderem A . A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature. 2011; 473(7348):463-9. DOI: 10.1038/nature10124. View

17.

de Titta A, Ballester M, Julier Z, Nembrini C, Jeanbart L, van der Vlies A . Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A. 2013; 110(49):19902-7. PMC: 3856841. DOI: 10.1073/pnas.1313152110. View

18.

Coffman R, Sher A, Seder R . Vaccine adjuvants: putting innate immunity to work. Immunity. 2010; 33(4):492-503. PMC: 3420356. DOI: 10.1016/j.immuni.2010.10.002. View

19.

Standley S, Mende I, Goh S, Kwon Y, Beaudette T, Engleman E . Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity. Bioconjug Chem. 2007; 18(1):77-83. DOI: 10.1021/bc060165i. View

20.

Lizotte P, Wen A, Sheen M, Fields J, Rojanasopondist P, Steinmetz N . In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat Nanotechnol. 2015; 11(3):295-303. PMC: 4777632. DOI: 10.1038/nnano.2015.292. View